Cardiovascular effects of GLP-1 and GLP-1-based therapies: implications for the cardiovascular continuum in diabetes?
Article first published online: 20 FEB 2013
© 2012 The Authors. Diabetic Medicine © 2012 Diabetes UK
Volume 30, Issue 3, pages 289–299, March 2013
How to Cite
Burgmaier, M., Heinrich, C. and Marx, N. (2013), Cardiovascular effects of GLP-1 and GLP-1-based therapies: implications for the cardiovascular continuum in diabetes?. Diabetic Medicine, 30: 289–299. doi: 10.1111/j.1464-5491.2012.03746.x
- Issue published online: 20 FEB 2013
- Article first published online: 20 FEB 2013
- Accepted manuscript online: 18 JUL 2012 04:12AM EST
- Accepted 7 June 2012
Diabet. Med. 30, 289–299 (2013)
Aims Glucagon-like peptide-1 receptor agonists and inhibitors of dipeptidyl peptidase-4 that increase glucagon-like peptide-1 plasma concentrations are current treatment options for patients with diabetes mellitus. As patients with diabetes are a high-risk population for the development of a severe and diffuse atherosclerosis, we aim to review the potential action of these drugs on cardiovascular disease and to summarize the potential role of present glucagon-like peptide-1-based therapies from a cardiologist’s point of view.
Methods Using a PubMed/MEDLINE search without language restriction, studies were identified and evaluated in order to review the effects of glucagon-like peptide-1-based therapy on different stages of the cardiovascular continuum.
Results Recent experimental as well as clinical data suggest that dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists—in addition to their metabolic effects—may have beneficial effects on the cardiovascular continuum at multiple stages, including: (1) cardiovascular risk factors; (2) molecular mechanisms involved in atherogenesis; (3) ischaemic heart disease; and (4) heart failure. Furthermore, retrospective analysis suggested decreased cardiovascular events in patients with glucagon-like peptide-1-based therapies.
Conclusion There are ample data to suggest beneficial effects of glucagon-like peptide-1-based therapies on the cardiovascular continuum and large-scale clinical trials are warranted to determine whether these effects translate into improved cardiovascular endpoints in humans.